Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Significant Decline in Short Interest

Posted by Donna Armstrong on Apr 12th, 2026

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) was the target of a large drop in short interest during the month of March. As of March 31st, there was short interest totaling 78,484 shares, a drop of 81.3% from the March 15th total of 419,845 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 845,596 shares, the short-interest ratio is presently 0.1 days.

Daiichi Sankyo Trading Down 1.1%

Shares of DSNKY stock opened at $17.57 on Friday. The company has a current ratio of 2.69, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. The stock has a market cap of $33.28 billion, a P/E ratio of 16.12, a price-to-earnings-growth ratio of 0.91 and a beta of -0.04. The stock has a 50 day simple moving average of $18.51 and a 200 day simple moving average of $21.42. Daiichi Sankyo has a 1 year low of $17.44 and a 1 year high of $28.21.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last issued its quarterly earnings results on Thursday, January 29th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.05. The business had revenue of $3.65 billion during the quarter, compared to analysts’ expectations of $3.88 billion. Daiichi Sankyo had a return on equity of 18.64% and a net margin of 14.83%. On average, research analysts predict that Daiichi Sankyo will post 0.73 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.